Premium
Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data
Author(s) -
Grana G.
Publication year - 2006
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.20564
Subject(s) - medicine , anastrozole , exemestane , letrozole , tamoxifen , aromatase , breast cancer , adjuvant , aromatase inhibitor , oncology , tolerability , adjuvant therapy , gynecology , randomized controlled trial , cancer , adverse effect
Tamoxifen is the established adjuvant treatment for postmenopausal women with hormone‐sensitive early breast cancer. However, the side‐effects associated with tamoxifen therapy have prompted a search for safer and potentially more effective endocrine agents. Results from randomized trials of the third‐generation aromatase inhibitors, anastrozole, letrozole and exemestane, demonstrating improved efficacy compared with tamoxifen and favorable tolerability profiles, are discussed in this review. J. Surg. Oncol. 2006;93:585–592. © 2006 Wiley‐Liss, Inc.